Keeping Pace: Advances in First-Line Therapy for EGFR-mutated NSCLC
Host: Mark A. Socinski, MD
Guest: Helena Yu, MD
Advances in treatment and new insights into the biology of epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC) have led to the development of treatments that significantly extend overall survival.
In this discussion, Drs. Mark Socinski and Helena Yu cover the latest scientific and clinical data on the emerging role of targeted therapies in EGFR mutation-positive NSCLC.